RT Journal Article
SR Electronic
T1 Clinical Arterial Spin-Labeling MR Imaging to Screen for Typical and Atypical Neurodegenerative Disease in the New Era of Alzheimer Treatment
JF American Journal of Neuroradiology
JO Am. J. Neuroradiol.
FD American Society of Neuroradiology
SP 632
OP 636
DO 10.3174/ajnr.A8164
VO 45
IS 5
A1 Lee, Kevin
A1 Mahmud, Meem
A1 Marx, Darby
A1 Yasen, Weiye
A1 Sharma, Omna
A1 Ivanidze, Jana
A1 Zan, Elcin
A1 Zhou, Liangdong
A1 Li, Yi
A1 de Leon, Mony J.
A1 Nordvig, Anna S.
A1 Chiang, Gloria C.
YR 2024
UL http://www.ajnr.org/content/45/5/632.abstract
AB SUMMARY: The clinical standard of care in the diagnosis of neurodegenerative diseases relies on [18F] FDG-PET/CT or PET MR imaging. Limitations of FDG-PET include cost, the need for IV access, radiation exposure, and availability. Arterial spin-labeling MR imaging has been shown in research settings to be useful as a proxy for FDG-PET in differentiating Alzheimer disease from frontotemporal dementia. However, it is not yet widely used in clinical practice, except in cerebrovascular disease. Here, we present 7 patients, imaged with our routine clinical protocol with diverse presentations of Alzheimer disease and other neurodegenerative diseases, in whom arterial spin-labeling–derived reduced CBF correlated with hypometabolism or amyloid/tau deposition on PET. Our case series illustrates the clinical diagnostic utility of arterial spin-labeling MR imaging as a fast, accessible, and noncontrast screening tool for neurodegenerative disease. Arterial spin-labeling MR imaging can guide patient selection for subsequent PET or fluid biomarker work-up, as well as for possible therapy with antiamyloid monoclonal antibodies.ADAlzheimer diseaseADLsactivities of daily livingASLarterial spin-labelingCIcognitive impairmentCOVID-19coronavirus 2019lvPPAlogopenic variant progressive aphasiaMCImild cognitive impairmentMoCAMontreal Cognitive AssessmentPCAposterior cortical atrophy